ESMO 2019: Results from SORCE clinical trial with adjuvant sorafenib
Results from the SORCE clinical trial to assess sorfenib as an adjuvant treatment for renal cell carcinoma (RCC) at intermediate or high risk of relapse were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. As for previous large randomised phase 3 clinical trials (ASSURE, PROTECT, and ATLAS) to […]